&w=3840&q=100)
Glenmark Pharma launches lung cancer treatment drug Tevimbra in India
Tevimbra is developed by BeiGene (now BeOne Medicines), a global oncology leader. This launch marks Glenmark's first foray into immune-oncology in India and is a major milestone in expanding its innovative oncology portfolio, the company said in a regulatory filing.
"At a time when the cancer burden is rising sharply, we are proud to enable oncologists and patients to access Tevimbra, a therapy with proven efficacy and safety outcomes, strong science, and meaningful impact," Glenmark Pharmaceuticals President and Business Head India Formulations Alok Malik said.
Immuno-oncology offers a promising future for the treatment of various types of advanced cancers, which are difficult to treat, he said, adding that "Our foray in this area marks a significant inflection point in our journey to build a world-class oncology portfolio that is innovative, inclusive and at the same time life-changing for patients".
Tevimbra is indicated for the treatment of first-line locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with chemotherapy and second-line treatment of locally advanced or metastatic NSCLC and oesophagal squamous cell carcinoma (ESCC) as monotherapy, the company said.
It is approved and marketed in multiple leading global markets, including the United States, European Union, Australia and China.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News18
3 hours ago
- News18
Small Drugmakers Supplying Medicines In Rural Areas Under Scrutiny; Centre Calls For Crackdown
Central Drugs Standard Control Organisation has conducted over 1,000 Risk-Based Inspections across the country and asked states/UTs to continue acting after finding non-compliance. Small pharmaceutical companies, especially those supplying medicines in rural areas, have come under regulatory scrutiny, with the Drug Controller General of India (DCGI) directing state officials to closely monitor their activities and ensure accountability. The DCGI has asked states, via state licensing authorities (SLAs) to take strict action against any such marketers found violating quality standards under the Drugs and Cosmetics Rules, 1945. The move comes amid growing concerns over the quality and compliance practices of certain small-scale players in the drug distribution chain. The apex drug regulatory agency has also called for stricter action against the repeated manufacture of spurious and Not of Standard Quality (NSQ) drugs and asked states to keep CDSCO informed of any regulatory actions taken. 'We are still awaiting response on Schedule M compliance and most small players are unable to cope up with quality scrutiny. The government is convinced that without proper oversight, these companies pose a risk to medicine safety in under-served regions," a senior government official privy to the development told News18. The official added that the apex regulatory authority, Central Drugs Standard Control Organisation (CDSCO) has conducted over 1,000 Risk-Based Inspections (RBIs) across the country. 'These inspections have been key in identifying non-compliance among drug manufacturers and strengthening the surveillance framework." The first is adoption of revised Schedule M. The DCGI has asked state officials to begin enforcing updated Good Manufacturing Practice norms for drug production units. Also, it has asked to fix new drug licensing gaps as state licensing officials have been asked to refrain from issuing product licences without proper permissions from DCGI. The officials have also been instructed 'Post risk based inspections action." The states and UTs have been urged to act on the findings and recommendations that emerge from inspections. CDSCO has informed officials to comply with '84AB" in which details of all drug makers and product details must be uploaded and verified on the central online portal to ensure traceability. Also, the state officials will work on building testing lab capacity which has been flagged as a 'critical need."
Hans India
2 days ago
- Hans India
‘Decide within 3 months': Delhi HC tells CDSCO on plea against use of diabetes drugs in weight management
New Delhi: The Delhi High Court on Wednesday directed the Central Drugs Standard Control Organisation (CDSCO) to decide, within 3 months, a representation raising safety concerns on the usage of GLP-1-RA drugs in weight management and aesthetic treatment. A bench of Chief Justice Devendra Upadhyaya and Justice Tushar Rao Gedela was hearing a public interest litigation (PIL) against the manner in which Glucagon Like Peptide -1 Receptor Agonist (RA) (GLP-1-RA) drugs, specifically semaglutide, tirzepatide, and liraglutide have been granted marketing approval in India for weight loss and aesthetic purposes, despite being originally approved for treatment of Type 2 diabetes. The PIL, filed through advocate Rohit Kumar, referred to the significant risks posed by these medications, including pancreatitis, gastrointestinal damage, thyroid and pancreatic cancers, cardiovascular complications, metabolic dysregulation, and optic neuropathy. In its order, the CJ Upadhyaya-led Bench directed the PIL litigant to submit to CDSCO the scientific studies and data relied upon in the petition. Asking the CDSCO to decide the representation within 3 months, the Delhi High Court closed the proceedings and disposed of the matter. As per the petition, GLP-1-RA drugs were originally developed and internationally approved for the treatment of Type 2 Diabetes Mellitus, but over the past few years, have been "repurposed and approved often through accelerated pathways for obesity treatment and chronic weight management, based largely on short-term efficacy trials". Questioning the CDSCO's grant of marketing approval of these drugs for weight loss purposes in the country, the plea cited limited safety data, lack of India-specific clinical trials, and absence of a robust pharmacovigilance or regulatory oversight mechanism. It said that there is no evidence to suggest that these drugs have undergone rigorous safety evaluation within the Indian population and highlighted the "aggressive" and "unregulated marketing" of these drugs for aesthetic and non-medical purposes. "Pharmaceutical companies, clinics, and digital wellness platforms are promoting semaglutide and tirzepatide as 'quick-fix' weight loss solutions, especially targeting younger populations, including teenagers. The increasing normalisation of these drugs in aesthetic medicine is alarming," added the PIL. Further, it said that the lack of transparency surrounding the clinical data submitted for approval of these drugs, the absence of publicly available safety profiles, and the regulatory silence on their off-label use violated the right to health, which encompasses the right to safe medication, informed decision-making, and access to scientific information.
Business Standard
2 days ago
- Business Standard
AstraZeneca Pharma gets CDSCO approval to import Durvalumab Solution
AstraZeneca Pharma India said that it has received permission from the Central Drugs Standard Control Organisation (CDSCO) to import for sale and distribution of Durvalumab Solution for infusion 120 mg/2.4 ml and 500 mg/10 ml (Imfinzi). Through this approval, Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with Durvalumab in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR). AstraZeneca Pharma is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in four therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory and Rare Disease. The companys consolidated net profit jumped 57.7% to Rs 62.27 crore on 25.4% increase in net sales to Rs 480.48 crore in Q4 FY25 over Q4 FY24. The scrip shed 0.13% to Rs 8,886.50 on the BSE.
